111 related articles for article (PubMed ID: 20354122)
1. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Squires MS; Cooke L; Lock V; Qi W; Lewis EJ; Thompson NT; Lyons JF; Mahadevan D
Mol Cancer Ther; 2010 Apr; 9(4):920-8. PubMed ID: 20354122
[TBL] [Abstract][Full Text] [Related]
2. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Santo L; Vallet S; Hideshima T; Cirstea D; Ikeda H; Pozzi S; Patel K; Okawa Y; Gorgun G; Perrone G; Calabrese E; Yule M; Squires M; Ladetto M; Boccadoro M; Richardson PG; Munshi NC; Anderson KC; Raje N
Oncogene; 2010 Apr; 29(16):2325-36. PubMed ID: 20101221
[TBL] [Abstract][Full Text] [Related]
3. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy.
Wei X; Nian J; Zheng J; He Y; Zeng M
Cancer Chemother Pharmacol; 2020 May; 85(5):949-957. PubMed ID: 32279103
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2019 Jun; 513(3):589-593. PubMed ID: 30979499
[TBL] [Abstract][Full Text] [Related]
7. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Chen R; Keating MJ; Gandhi V; Plunkett W
Blood; 2005 Oct; 106(7):2513-9. PubMed ID: 15972445
[TBL] [Abstract][Full Text] [Related]
8. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer.
Kang MA; Kim W; Jo HR; Shin YJ; Kim MH; Jeong JH
Int J Oncol; 2018 Aug; 53(2):703-712. PubMed ID: 29901072
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
[TBL] [Abstract][Full Text] [Related]
10. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Gojo I; Zhang B; Fenton RG
Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
[TBL] [Abstract][Full Text] [Related]
11. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
[TBL] [Abstract][Full Text] [Related]
12. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
13. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
Wang L; Chen Y; Li H; Xu Q; Liu R
Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
[TBL] [Abstract][Full Text] [Related]
14. A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.
Chen EX; Hotte S; Hirte H; Siu LL; Lyons J; Squires M; Lovell S; Turner S; McIntosh L; Seymour L
Br J Cancer; 2014 Dec; 111(12):2262-7. PubMed ID: 25393368
[TBL] [Abstract][Full Text] [Related]
15. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
Rosato RR; Almenara JA; Cartee L; Betts V; Chellappan SP; Grant S
Mol Cancer Ther; 2002 Feb; 1(4):253-66. PubMed ID: 12467221
[TBL] [Abstract][Full Text] [Related]
16. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
17. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
18. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.
Mahadevan D; Plummer R; Squires MS; Rensvold D; Kurtin S; Pretzinger C; Dragovich T; Adams J; Lock V; Smith DM; Von Hoff D; Calvert H
Ann Oncol; 2011 Sep; 22(9):2137-2143. PubMed ID: 21325451
[TBL] [Abstract][Full Text] [Related]
19. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
